The Role of Platelet Rich Plasma (PRP) and Other Biologics for Rotator Cuff Repair
Joshua A. Greenspoon1, Samuel G. Moulton1, Peter J. Millett1, 2, *, Maximilian Petri1, 2
Identifiers and Pagination:Year: 2016
Issue: Suppl 1: M6
First Page: 309
Last Page: 314
Publisher ID: TOORTHJ-10-309
Article History:Received Date: 02/08/2015
Revision Received Date: 07/08/2015
Acceptance Date: 1/02/2016
Electronic publication date: 21/07/2016
Collection year: 2016
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Surgical treatment of rotator cuff tears has consistently demonstrated good clinical and functional outcomes. However, in some cases, the rotator cuff fails to heal. While improvements in rotator cuff constructs and biomechanics have been made, the role of biologics to aid healing is currently being investigated.
A selective literature search was performed and personal surgical experiences are reported.
Biologic augmentation of rotator cuff repairs can for example be performed wtableith platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs). Clinical results on PRP application have been controversial. Application of MSCs has shown promise in animal studies, but clinical data on its effectiveness is presently lacking. The role of Matrix Metalloproteinase (MMP) inhibitors is another interesting field for potential targeted drug therapy after rotator cuff repair.
Large randomized clinical studies need to confirm the benefit of these approaches, in order to eventually lower retear rates and improve clinical outcomes after rotator cuff repair.